



## Clinical trial results:

### Transplantation of umbilical cord blood from unrelated donors in patients with haematological diseases using a myeloablative conditioning regimen

#### Summary

EudraCT number	2009-011818-21
Trial protocol	GB
Global end of trial date	12 May 2015

#### Results information

Result version number	v1 (current)
This version publication date	16 February 2018
First version publication date	16 February 2018

#### Trial information

##### Trial identification

Sponsor protocol code	UCL/09/0128
-----------------------	-------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02310997
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	University College London Cancer Trial Centre (UCL CTC)
Sponsor organisation address	90 Tottenham Court Road, London, United Kingdom, W1T 4TJ
Public contact	University College London & Cancer Trial Centre, University College London & Cancer Trial Centre, +44 2076799860, ctc.cordblood@ucl.ac.uk
Scientific contact	University College London & Cancer Trial Centre, University College London & Cancer Trial Centre, +44 2076799860, ctc.cordblood@ucl.ac.uk

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

Analysis stage	Final
Date of interim/final analysis	16 January 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	12 May 2015
Global end of trial reached?	Yes
Global end of trial date	12 May 2015
Was the trial ended prematurely?	Yes

Notes:

---

**General information about the trial**

Main objective of the trial:

To assess the safety and efficacy of unrelated donor umbilical cord blood transplantation (UCBT) in a multi-institution UK setting where the use of a myeloablative preparative regimen is indicated. The anti-malignancy effect of this treatment is achieved by a combination of intensive chemoradiotherapy and the 'graft vs. malignancy' (GVM) effect. The advantage of this approach is the increased likelihood of destroying the malignant cells and a reduced risk of graft rejection as the bone marrow is better prepared to accept the transplant than with reduced intensity conditioning. However, the treatment may be less well tolerated by some patients and therefore patients of advanced age or with impaired organ function were not eligible for this trial.

Protection of trial subjects:

Patients underwent screening evaluations to confirm eligibility for the trial, these included: medical history, full blood count, biochemistry tests (liver and renal function), clotting screen, bone marrow biopsy to confirm diagnosis, infection screening, and electrocardiogram (ECG). Furthermore, all patients undergoing total body irradiation as part of their conditioning regimen had to be assessed by a radiation oncologist prior to admission to the trial.

A cord blood unit selection committee was established to assist in selecting appropriate units for specific patients. Sites were strongly encouraged to consult the selection committee. Units were selected preferentially from cord blood banks that had achieved FACT-NetCord accreditation to ensure the quality of the products used. An appropriate back up umbilical cord blood graft for each patient was reserved until engraftment had been observed.

Patients were monitored regularly post-transplant with FBC and biochemistry investigations carried out daily until engraftment and discharge. The protocol provided instructions for supportive care measures to address anaemia, thrombocytopenia, fever and nutrition.

The protocol advised levels of antibiotic, anti-fungal, anti-viral and anticonvulsant prophylaxis, and treatment for the prevention of tumour lysis and engraftment syndromes. Ciclosporin dose modifications were permitted based upon serum creatinine levels.

---

Background therapy:

Not applicable

Evidence for comparator:

Not applicable - no comparator used

Actual start date of recruitment	08 August 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

---

Country: Number of subjects enrolled	United Kingdom: 11
Worldwide total number of subjects	11
EEA total number of subjects	11

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	1
Children (2-11 years)	1
Adolescents (12-17 years)	1
Adults (18-64 years)	8
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

A total of 60 patients were to be recruited over a period of 36 months. The first site was opened on 29/07/2011, and the first patient recruited on 08/08/2011. The trial closed to recruitment early on 19/12/2013 due to poor recruitment. A total of 11 patients were recruited across 7 sites.

### Pre-assignment

Screening details:

Screening logs were requested from all active sites on 09/09/2013.

Twenty patients were screened for the study.

Nine of the twenty screened patients did not enter the trial for the following reasons:

Unsuitable for total body irradiation = 5

Eligibility criteria = 3

Incorrect consent version = 1

### Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Blinding implementation details:

n/a

### Arms

Are arms mutually exclusive?	Yes
Arm title	Flu/Cyc/TBI

Arm description:

Patients aged 2-45 years (excluding AML, JMML and MDS patients aged <16 years) received a myeloablative conditioning regimen comprising:

Fludarabine

Cyclophosphamide

Total body irradiation (13 - 14.4 Gy in 8 fractions)

It was permissible to follow local policy for scheduling of TBI and cyclophosphamide providing there was no change in the dose or number of fractions.

Conditioning regimens began 9 days pre-transplant with patients receiving an unrelated donor umbilical cord blood transplant on day 0.

Arm type	Experimental
Investigational medicinal product name	Fludarabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solution for solution for injection
Routes of administration	Intravenous drip use

Dosage and administration details:

Fludarabine 25 mg/m<sup>2</sup>/day

Intravenous infusion over 30 minutes to 1 hour

Days -8, -7 and -6, pre-transplant

Total dose 75 mg/m<sup>2</sup>

Investigational medicinal product name	Cyclophosphamide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solution for solution for injection
Routes of administration	Intravenous drip use

Dosage and administration details:

Cyclophosphamide 60mg/kg/day

To be administered intravenously with high volume fluid flush and mesna according to local policy on day -7 and -6 pre-transplant, or day -3 and -2 pre-transplant

Total dose 120mg/kg

<b>Arm title</b>	Bu/Cyc/Mel
------------------	------------

Arm description:

Patients aged < 2 years and AML, JMML and MDS patients <16 years received a myeloablative conditioning regimen comprising:

Busulfan

Cyclophosphamide

Melphalan

Conditioning regimens began 10 days pre-transplant with patients receiving an unrelated donor umbilical cord blood transplant on day 0.

Arm type	Experimental
Investigational medicinal product name	Cyclophosphamide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solution for solution for injection
Routes of administration	Intravenous drip use

Dosage and administration details:

Cyclophosphamide 60mg/kg/day

To be administered intravenously with high volume fluid flush and mesna according to local policy on either, day -4 and -3 pre-transplant

Total dose 120mg/kg

Investigational medicinal product name	Busulfan
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous drip use

Dosage and administration details:

Busulfan 3.2mg/kg/day on day -9, -8, -7 and -6 pre transplant

Busulfan was given in 2 or 4 doses per day as per local policy (suggested schedules for administration were: 0.8mg/kg IV over 2 hours qds, or 1.6mg/kg IV over 3 hours bd)

Investigational medicinal product name	Melphalan
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for injection
Routes of administration	Intravenous drip use

Dosage and administration details:

Melphalan 140mg/m<sup>2</sup> on day -2 pre transplant

IV infusion over 15 minutes - 1 hour

<b>Number of subjects in period 1</b>	Flu/Cyc/TBI	Bu/Cyc/Mel
Started	10	1
Completed	10	1

## Baseline characteristics

### Reporting groups

Reporting group title	Flu/Cyc/TBI
-----------------------	-------------

Reporting group description:

Patients aged 2-45 years (excluding AML, JMML and MDS patients aged <16 years) received a myeloablative conditioning regimen comprising:

Fludarabine

Cyclophosphamide

Total body irradiation (13 - 14.4 Gy in 8 fractions)

It was permissible to follow local policy for scheduling of TBI and cyclophosphamide providing there was no change in the dose or number of fractions.

Conditioning regimens began 9 days pre-transplant with patients receiving an unrelated donor umbilical cord blood transplant on day 0.

Reporting group title	Bu/Cyc/Mel
-----------------------	------------

Reporting group description:

Patients aged < 2 years and AML, JMML and MDS patients <16 years received a myeloablative conditioning regimen comprising:

Busulfan

Cyclophosphamide

Melphalan

Conditioning regimens began 10 days pre-transplant with patients receiving an unrelated donor umbilical cord blood transplant on day 0.

Reporting group values	Flu/Cyc/TBI	Bu/Cyc/Mel	Total
Number of subjects	10	1	11
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	1	1
Children (2-11 years)	1	0	1
Adolescents (12-17 years)	1	0	1
Adults (18-64 years)	8	0	8
From 65-84 years	0	0	0
85 years and over	0	0	0
Gender categorical			
Units: Subjects			
Female	4	0	4
Male	6	1	7
Disease type			
Units: Subjects			
Acute Myelogenous Leukaemia	6	0	6
Acute Lymphoblastic Leukaemia	4	1	5
Lines of prior treatment			
Units: Subjects			
One	1	0	1
Two	6	1	7

Three	1	0	1
Four	2	0	2

---



## End points

### End points reporting groups

Reporting group title	Flu/Cyc/TBI
-----------------------	-------------

Reporting group description:

Patients aged 2-45 years (excluding AML, JMML and MDS patients aged <16 years) received a myeloablative conditioning regimen comprising:

Fludarabine

Cyclophosphamide

Total body irradiation (13 - 14.4 Gy in 8 fractions)

It was permissible to follow local policy for scheduling of TBI and cyclophosphamide providing there was no change in the dose or number of fractions.

Conditioning regimens began 9 days pre-transplant with patients receiving an unrelated donor umbilical cord blood transplant on day 0.

Reporting group title	Bu/Cyc/Mel
-----------------------	------------

Reporting group description:

Patients aged < 2 years and AML, JMML and MDS patients <16 years received a myeloablative conditioning regimen comprising:

Busulfan

Cyclophosphamide

Melphalan

Conditioning regimens began 10 days pre-transplant with patients receiving an unrelated donor umbilical cord blood transplant on day 0.

### Primary: Non-relapse mortality at day 100

End point title	Non-relapse mortality at day 100 <sup>[1]</sup>
-----------------	---

End point description:

The proportion of patients that have not relapsed but died within 100 days of transplant. Non-relapse mortality greater or equal to 50% within 100 days of transplant would have stopped the study.

End point type	Primary
----------------	---------

End point timeframe:

Measured at 100 days post-transplant.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This primary endpoint represents numbers of patients. No specific statistical analysis is necessary to establish numbers of patients. Furthermore, due to the small sample size, statistical analysis would not be possible.

End point values	Flu/Cyc/TBI	Bu/Cyc/Mel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	1		
Units: Percentage	10	0		

### Statistical analyses

No statistical analyses for this end point

**Secondary: Overall survival at one year**

End point title	Overall survival at one year
End point description: Proportion of patients alive one year after transplant	
End point type	Secondary
End point timeframe: 1 year after transplant	

<b>End point values</b>	Flu/Cyc/TBI	Bu/Cyc/Mel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	1		
Units: Percentage	70	100		

<b>Attachments (see zip file)</b>	MAC-UCBT survival curve/MAC-UCBT survival curve 11012018.
-----------------------------------	---

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Neutrophil recovery**

End point title	Neutrophil recovery
End point description: Proportion of patients with neutrophil recovery by day 42.	
End point type	Secondary
End point timeframe: From day of transplant to day 42 post-transplant.	

<b>End point values</b>	Flu/Cyc/TBI	Bu/Cyc/Mel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	1		
Units: Percentage	89	100		

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Incidence of GvHD**

End point title	Incidence of GvHD
-----------------	-------------------

End point description:

The number of patients experiencing acute or chronic GvHD 100 days or 1 year after their transplant respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Incidence of acute GvHD = from transplant to 100 days post-transplant

Incidence of chronic GvHD = from transplant to 1 year post-transplant

End point values	Flu/Cyc/TBI	Bu/Cyc/Mel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	1		
Units: Percentage				
Acute GvHD	50	100		
Chronic GvHD	40	0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Platelet recovery

End point title	Platelet recovery
-----------------	-------------------

End point description:

Proportion of patients with platelet recovery by day 100. Platelet recovery was defined as  $75 \times 10^9/l$ .

End point type	Secondary
----------------	-----------

End point timeframe:

From day of transplant to day 100 post-transplant.

End point values	Flu/Cyc/TBI	Bu/Cyc/Mel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8	1		
Units: Percentage	100	100		

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

The reporting period for adverse events was from informed consent to 42 days post-transplant.

Adverse event reporting additional description:

The following events were exempt from SAE reporting:

- disease progression (including disease related deaths)
- the following treatment-related events:

infection (grades 1-3)

graft failure

acute GvHD

chronic GvHD

secondary malignancy

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	CTCAE
Dictionary version	4.03

### Reporting groups

Reporting group title	Flu/Cyc/TBI
-----------------------	-------------

Reporting group description: -

Reporting group title	Bu/Cyc/Mel
-----------------------	------------

Reporting group description: -

Serious adverse events	Flu/Cyc/TBI	Bu/Cyc/Mel	
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 10 (20.00%)	0 / 1 (0.00%)	
number of deaths (all causes)	3	0	
number of deaths resulting from adverse events	1	0	
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Intracranial hemorrhage			
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Pneumonia	Additional description: non-CTCAE term		

subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Flu/Cyc/TBI	Bu/Cyc/Mel	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 10 (100.00%)	1 / 1 (100.00%)	
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Hypotension			
subjects affected / exposed	3 / 10 (30.00%)	0 / 1 (0.00%)	
occurrences (all)	3	0	
Tachycardia	Additional description: non-CTCAE term		
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
Cold sore	Additional description: non CTCAE term		
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Fatigue			
subjects affected / exposed	4 / 10 (40.00%)	1 / 1 (100.00%)	
occurrences (all)	4	1	
Fever			
subjects affected / exposed	10 / 10 (100.00%)	1 / 1 (100.00%)	
occurrences (all)	10	1	
Pain	Additional description: non CTCAE term		
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Chest pain	Additional description: non CTCAE term		
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Immune system disorders			

Allergy subjects affected / exposed occurrences (all)	Additional description: non CTCAE term		
	4 / 10 (40.00%)	0 / 1 (0.00%)	
	4	0	
Reproductive system and breast disorders Vaginal haemorrhage subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 1 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders Bronchospasm subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 1 (100.00%) 1	
Cough subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	0 / 1 (0.00%) 0	
Pleural effusion subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 1 (0.00%) 0	
Shortness of breath subjects affected / exposed occurrences (all)	Additional description: non-CTCAE term		
	1 / 10 (10.00%)	0 / 1 (0.00%)	
	1	0	
Epistaxis subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 1 (0.00%) 0	
Psychiatric disorders Depression subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	0 / 1 (0.00%) 0	
Anxiety subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 1 (0.00%) 0	
Hallucination subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 1 (0.00%) 0	
Insomnia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 1 (0.00%) 0	

Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Blood bilirubin increased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Weight loss			
subjects affected / exposed	5 / 10 (50.00%)	0 / 1 (0.00%)	
occurrences (all)	5	0	
Injury, poisoning and procedural complications			
Engraftment syndrome	Additional description: non CTCAE term		
subjects affected / exposed	0 / 10 (0.00%)	1 / 1 (100.00%)	
occurrences (all)	0	1	
Post-operative haemorrhage			
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Haemorrhage	Additional description: non CTCAE term		
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Headache			
subjects affected / exposed	2 / 10 (20.00%)	0 / 1 (0.00%)	
occurrences (all)	2	0	
Dysgeusia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	7 / 10 (70.00%)	1 / 1 (100.00%)	
occurrences (all)	7	1	
Fluid overload	Additional description: non-CTCAE term		

subjects affected / exposed	2 / 10 (20.00%)	0 / 1 (0.00%)	
occurrences (all)	2	0	
Neutropenia			
subjects affected / exposed	7 / 10 (70.00%)	1 / 1 (100.00%)	
occurrences (all)	7	1	
Thrombocytopenia			
subjects affected / exposed	2 / 10 (20.00%)	0 / 1 (0.00%)	
occurrences (all)	2	0	
Leukopenia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Eye disorders			
Visual disturbance	Additional description: non CTCAE term		
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	4 / 10 (40.00%)	0 / 1 (0.00%)	
occurrences (all)	4	0	
Anal pain			
subjects affected / exposed	1 / 10 (10.00%)	1 / 1 (100.00%)	
occurrences (all)	1	1	
Constipation			
subjects affected / exposed	2 / 10 (20.00%)	0 / 1 (0.00%)	
occurrences (all)	2	0	
Diarrhoea			
subjects affected / exposed	6 / 10 (60.00%)	1 / 1 (100.00%)	
occurrences (all)	6	1	
Dry mouth			
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Heartburn	Additional description: non-CTCAE term		
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Mucositis	Additional description: includes both oral and anal mucositis		



subjects affected / exposed	10 / 10 (100.00%)	1 / 1 (100.00%)	
occurrences (all)	10	1	
Nausea			
subjects affected / exposed	10 / 10 (100.00%)	1 / 1 (100.00%)	
occurrences (all)	10	1	
Vomiting			
subjects affected / exposed	5 / 10 (50.00%)	0 / 1 (0.00%)	
occurrences (all)	5	0	
Hepatobiliary disorders			
Hepatic impairment	Additional description: non CTCAE term		
subjects affected / exposed	2 / 10 (20.00%)	0 / 1 (0.00%)	
occurrences (all)	2	0	
Skin and subcutaneous tissue disorders			
Rash	Additional description: non CTCAE term		
subjects affected / exposed	8 / 10 (80.00%)	1 / 1 (100.00%)	
occurrences (all)	8	1	
Alopecia			
subjects affected / exposed	2 / 10 (20.00%)	0 / 1 (0.00%)	
occurrences (all)	2	0	
Pain of skin			
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Dysurea	Additional description: non CTCAE term		
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Haematuria	Additional description: non-CTCAE term		
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	

Leg cramps subjects affected / exposed occurrences (all)	Additional description: non CTCAE term		
	1 / 10 (10.00%) 1	0 / 1 (0.00%) 0	
Muscular and bone pain subjects affected / exposed occurrences (all)	Additional description: non CTCAE term		
	1 / 10 (10.00%) 1	0 / 1 (0.00%) 0	
Neck pain subjects affected / exposed occurrences (all)	Additional description: non CTCAE term		
	1 / 10 (10.00%) 1	0 / 1 (0.00%) 0	
Infections and infestations Urinary tract infection subjects affected / exposed occurrences (all)	Additional description: non CTCAE term		
	1 / 10 (10.00%) 1	0 / 1 (0.00%) 0	
Neutropenic sepsis subjects affected / exposed occurrences (all)	Additional description: non CTCAE term		
	1 / 10 (10.00%) 1	0 / 1 (0.00%) 0	
Metabolism and nutrition disorders Anorexia subjects affected / exposed occurrences (all)  Hypoalbuminaemia subjects affected / exposed occurrences (all)  Hypocalcaemia subjects affected / exposed occurrences (all)  Hypokalaemia subjects affected / exposed occurrences (all)  Hypomagnesaemia subjects affected / exposed occurrences (all)  Hyponatraemia subjects affected / exposed occurrences (all)  Hypophosphataemia	Additional description: non CTCAE term		
	4 / 10 (40.00%) 4	0 / 1 (0.00%) 0	
	1 / 10 (10.00%) 1	0 / 1 (0.00%) 0	
	2 / 10 (20.00%) 2	0 / 1 (0.00%) 0	
	2 / 10 (20.00%) 2	0 / 1 (0.00%) 0	
	2 / 10 (20.00%) 2	0 / 1 (0.00%) 0	
	1 / 10 (10.00%) 1	0 / 1 (0.00%) 0	

subjects affected / exposed	1 / 10 (10.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

- |  |
|--|
| <ol style="list-style-type: none"><li>1. Trial closed to recruitment early. Patients were still followed up.</li><li>2. Occurrence of non-serious AEs cannot be provided as only data on the highest grade experienced by patient was collected; the number of subjects affected is entered instead.</li></ol> |
|--|

Notes: